Galmed Pharmaceuticals Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GLMD Nasdaq 2830 www.galmedpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - Apr 17th, 2025 12:30 pm
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Apr 15th, 2025 12:30 pm
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - Apr 10th, 2025 12:00 pm
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - Apr 2nd, 2025 8:10 pm
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - Mar 20th, 2025 12:55 pm
Galmed Pharmaceuticals: Q3 Earnings Snapshot - Nov 15th, 2024 1:29 pm
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - Sep 25th, 2024 12:00 pm
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - Sep 19th, 2024 11:00 am